“Overall, our findings suggest that PDX1 plays a tumor-promoting role in human PCa cells by influencing expression of metabolites in insulin, inflammatory, and epithelial-mesenchymal transition (EMT) signaling pathways.”
Prostate cancer is the most commonly diagnosed cancer among men and remains a leading cause of cancer-related death worldwide. While age, family history, and genetics are well-established risk factors, researchers have increasingly focused on the role of metabolic health in prostate cancer progression. Obesity, insulin resistance, type 2 diabetes, and chronic inflammation have all been associated with more aggressive disease, but the molecular mechanisms connecting these conditions to prostate cancer remain incompletely understood.
A research paper titled “Epigenetic dysregulation and biological function of PDX1 in prostate cancer” was published in Volume 17 of Oncotarget. In this study, the researchers investigated whether a gene best known for regulating pancreatic function may also play an important role in prostate tumor biology. The study was led by first author Tayo A. Adeyika and corresponding author Bernard Kwabi-Addo from Howard University, Washington, DC.
A Metabolic Gene Enters the Prostate Cancer Spotlight
PDX1 (Pancreatic and Duodenal Homeobox 1) is a transcription factor that plays a critical role in pancreatic development and insulin production. In pancreatic beta cells, PDX1 helps regulate glucose homeostasis and insulin gene expression. Altered PDX1 activity has previously been linked to metabolic disorders, including obesity and type 2 diabetes.
However, far less is known about its role in prostate cancer.
The researchers became interested in PDX1 after analyzing genome-wide DNA methylation data from prostate tissues. They discovered that the PDX1 gene was significantly hypermethylated in prostate cancer compared with normal prostate tissue. Surprisingly, despite this increase in DNA methylation, prostate tumors also exhibited substantially higher PDX1 protein expression. Tissue microarray analysis revealed approximately 2.3-fold higher PDX1 expression in cancer tissues than in matched normal prostate samples.
This finding highlights the complexity of epigenetic regulation in cancer. While DNA methylation is often associated with gene silencing, methylation occurring within gene-body regions can sometimes correlate with increased gene expression. The authors suggest that this mechanism may help explain the elevated PDX1 expression observed in prostate tumors.
Evidence That PDX1 Promotes Tumor Growth
To determine whether PDX1 actively contributes to prostate cancer progression, the investigators manipulated PDX1 expression in two prostate cancer cell lines: androgen-dependent LNCaP cells and androgen-independent PC-3 cells.
When PDX1 was overexpressed, cancer cells proliferated more rapidly and demonstrated enhanced migratory behavior. In contrast, suppressing PDX1 using shRNA significantly reduced cell growth and impaired cell migration and invasion. These gain-of-function and loss-of-function experiments consistently pointed toward a tumor-promoting role for PDX1.
The findings suggest that PDX1 is not simply associated with prostate cancer but may actively participate in biological processes that support tumor expansion and dissemination.
Connecting Insulin Signaling and Cancer
One of the most notable findings was the effect of PDX1 on genes involved in insulin-related signaling pathways.
The researchers found that PDX1 overexpression increased expression of the insulin receptor (INSR) and insulin-like growth factor 1 receptor (IGF1R), two signaling molecules that have long been implicated in cancer cell growth, metabolism, and survival. Conversely, reducing PDX1 expression decreased the activity of these pathways.
These observations are particularly interesting because elevated insulin and IGF signaling are common features of obesity and insulin resistance. The results raise the possibility that PDX1 may help translate metabolic abnormalities into biological signals that promote prostate cancer progression.
The study also identified an inverse relationship between PDX1 and ESR2, the gene encoding estrogen receptor beta (ERβ), which has frequently been associated with tumor-suppressive effects in the prostate.
Driving Cellular Changes Associated With Metastasis
The investigators also explored whether PDX1 influences epithelial-mesenchymal transition (EMT), a process that enables cancer cells to become more mobile and invasive.
EMT is characterized by changes in gene expression that help tumor cells detach from their original location, invade surrounding tissues, and eventually spread to distant organs. The researchers found that increased PDX1 expression was associated with elevated levels of several important EMT regulators, including SNAI1, TWIST1, and CDH2. Suppressing PDX1 produced the opposite effect.
These findings suggest that PDX1 may contribute to metastatic potential by activating pathways that promote cellular plasticity and migration.
High Glucose Amplifies PDX1 Activity
Because PDX1 is fundamentally involved in glucose regulation, the researchers examined how prostate cancer cells responded to different glucose concentrations.
They discovered that high-glucose conditions intensified several PDX1-associated effects, particularly those related to proliferation, insulin signaling, and EMT. Cells overexpressing PDX1 showed greater proliferation and stronger activation of genes involved in insulin signaling and EMT when exposed to elevated glucose levels. In contrast, PDX1 knockdown cells exhibited reduced responsiveness to glucose stimulation.
This observation may have important clinical implications. Hyperglycemia is common among individuals with diabetes and metabolic syndrome, conditions that have been linked to poorer prostate cancer outcomes. The findings suggest that elevated glucose levels may create an environment that amplifies PDX1-driven tumor-promoting pathways.
Why These Findings Matter
The study places PDX1 at the intersection of several biological processes that are increasingly recognized as important in prostate cancer, including insulin signaling, inflammation, metabolic regulation, and epithelial-mesenchymal transition.
Rather than acting through a single pathway, PDX1 appears to function as a broader regulatory factor that influences multiple signaling networks involved in tumor growth and progression. Its ability to integrate metabolic and oncogenic signals may help explain why obesity, diabetes, and prostate cancer often appear biologically interconnected.
Looking Ahead
The authors conclude that PDX1 functions as an important regulator of prostate cancer biology and that its effects become particularly pronounced under high-glucose conditions. Their findings support a model in which PDX1 contributes to tumor growth, migration, and metabolic adaptation through coordinated effects on insulin signaling, inflammatory pathways, and EMT-related genes.
Although additional studies will be needed to determine whether PDX1 can be used clinically as a biomarker or therapeutic target, this work provides new insight into how metabolic dysfunction may influence prostate cancer progression. As researchers continue to explore the relationship between cancer and metabolism, PDX1 may represent an important molecular bridge connecting metabolic dysfunction and prostate cancer progression.
Click here to read the full research paper published in Oncotarget.
_______
Oncotarget is an open-access, peer-reviewed journal that has published primarily oncology-focused research papers since 2010. These papers are available to readers (at no cost and free of subscription barriers) in a continuous publishing format at Oncotarget.com.
Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
Click here to subscribe to Oncotarget publication updates.
For media inquiries, please contact media@impactjournals.com.